江西宏柏新材料股份有限公司 2025年第二次临时股东大会会议资料 江西宏柏新材料股份有限公司 2025年第二次临时股东大会 会议资料 2025年7月 1 江西宏柏新材料股份有限公司 2025年第二次临时股东大会会议资料 目录 | 一、2025年第二次临时股东大会会议须知 3 | | --- | | 二、2025年第二次临时股东大会议程 5 | 三、2025年第二次临时股东大会议案 | 议案一：《关于开展商品期货套期保值、期货交易业务的议案》 | | --- | | 7 | 2 江西宏柏新材料股份有限公司 2025年第二次临时股东大会会议资料 江西宏柏新材料股份有限公司 2025年第二次临时股东大会会议须知 各位股东及股东授权代表： 为维护投资者的合法权益，保证股东大会的正常秩序和议事效率，确保本次股东大 会的顺利召开，江西宏柏新材料股份有限公司（以下简称"本公司"或"公司"）根据 《中华人民共和国公司法》（以下简称"《公司法》"）、中国证监会《上市公司股东 会规则》、《江西宏柏新材料股份有限公司章程》（以下简称"《公司章程》"）等有 关规定，特制定本会议须知如下： 一、各股东及股东授权代表请按照本次股东大会通 ...

江西宏柏新材料股份有限公司 江西宏柏新材料股份有限公司 2025年第二次临时股东大会会议资料 2025年第二次临时股东大会 会议资料 2025年7月 1 江西宏柏新材料股份有限公司 2025年第二次临时股东大会会议资料 目录 | | | 二、2025年第二次临时股东大会议程........................................................................................ 5 三、2025年第二次临时股东大会议案 议案一：《关于开展商品期货套期保值、期货交易业务的议案》........................................ 7 2025年第二次临时股东大会会议须知 各位股东及股东授权代表： 为维护投资者的合法权益，保证股东大会的正常秩序和议事效率，确保本次股东大 会的顺利召开，江西宏柏新材料股份有限公司（以下简称"本公司"或"公司"）根据 《中华人民共和国公司法》（以下简称"《公司法》"）、中国证监会《上市公司股东 会规则》、《江西宏柏新材料股份有限公司章程》（以下简称"《公司章程》"）等有 关规定，特制定本 ...

Group 1 - The company announced the expiration of the third lock-up period for its 2022 employee stock ownership plan, which will end on June 23, 2025 [2][4] - As of the announcement date, the employee stock ownership plan holds 2.4 million shares, accounting for 0.38% of the company's total share capital [3][4] - The employee stock ownership plan has a total duration of 48 months, with shares being unlocked in three phases: 30% after 12 months, 30% after 24 months, and 40% after 36 months [3][4] Group 2 - The company has set performance targets for 2024, requiring a net profit of no less than 400 million yuan or an operating income of no less than 2.5 billion yuan [4] - If the company fails to meet the performance targets, all corresponding unlockable shares will not be released, and the management committee will sell the unallocated shares [4][5] - The company will continue to comply with market trading rules and regulations during the remaining duration of the employee stock ownership plan [6][7] Group 3 - The company plans to use part of its idle raised funds for cash management, with a maximum of 700 million yuan allocated for investment in safe and liquid financial products [15][30] - The company has already redeemed 40 million yuan from a previous investment in a bank deposit, earning 330,000 yuan in returns [16][18] - The cash management strategy aims to enhance the efficiency and returns of the raised funds while ensuring that the funds are not used for purposes that could harm shareholder interests [29][36]

Group 1 - Beixin Road and Bridge's application for issuing shares to specific targets has been approved by the Shenzhen Stock Exchange, pending approval from the China Securities Regulatory Commission [1] - Wangbian Electric's shareholders plan to reduce their holdings by a total of up to 2.99% of the company's shares, with specific reductions detailed for each shareholder [1] - Guotou Zhonglu is planning a major asset restructuring, leading to a suspension of its stock trading for up to 10 trading days [2] Group 2 - Baiotai has signed a licensing agreement with SteinCares for the commercialization of BAT2406 in Brazil and Latin America, with total payments potentially reaching up to $10 million [3] - Dongfang Bio has obtained two medical device registration certificates for its products, which are valid until June 1, 2030 [4] - Pulaike's subsidiary has received a new veterinary drug registration certificate [5] Group 3 - Wanyi Technology has signed an agreement to establish a joint laboratory with the Energy Research Institute, with a total research and development budget of 6 million yuan [6] - Yingboer plans to use up to 300 million yuan of idle funds for financial management [7] - Blue Biological has received two new veterinary drug registration certificates [8] Group 4 - Jinkai New Energy intends to inject up to 1.247 billion yuan into its wholly-owned subsidiary to enhance its operational capabilities [9] - China Pacific Insurance's assistant general manager's qualification has been approved [10] - Zhaoyan New Drug is reducing its registered capital and notifying creditors [11] Group 5 - Weili Medical plans to invest 37.5 million yuan in establishing a medical industry investment fund [12] - Hongbai New Materials has signed a deposit agreement for idle raised funds [13] - Tongyou Technology is applying for a credit limit of 10 million yuan from a bank [14] Group 6 - Warner Pharmaceutical's subsidiary has received approval for its magnesium sulfate raw material drug [15] - Fuda Co. plans to establish a wholly-owned subsidiary with a capital contribution of 475 million yuan [16] - Yabao Pharmaceutical has obtained a loan commitment letter for stock repurchase of up to 90 million yuan [17] Group 7 - Zhongyin Securities' chairman has resigned due to work adjustments [18] - Aili Home has terminated its share reduction plan ahead of schedule [19] - Samsung New Materials has appointed a new financial officer [20] Group 8 - Guobang Pharmaceutical's subsidiary has received EU GMP certification for its product [21] - Yipin Hong has received a drug registration certificate for its injection solution [22] - Wenzhou Hongfeng's subsidiary has obtained a utility model patent certificate [23] Group 9 - Cangge Mining plans to sign a financial service agreement with Zijin Mining Group [24] - Naipu Mining's application for convertible bonds has been accepted by the Shenzhen Stock Exchange [25] - Shenyang Machine Tool has completed its major asset restructuring [26] Group 10 - Xinlaifu plans to distribute a cash dividend of 5 yuan per 10 shares [27] - Jiashitang plans to distribute a cash dividend of 1.7 yuan per 10 shares [28] - Manbuer plans to distribute a cash dividend of 2.5 yuan per 10 shares [29] Group 11 - Guo Wang Yingda plans to distribute a cash dividend of 0.51 yuan per 10 shares [30] - Changsha Bank's shareholder plans to reduce holdings by up to 0.92% [31] - Hu Nong Commercial Bank plans to distribute a cash dividend of 1.93 yuan per 10 shares [32] Group 12 - Huaxiang Co. plans to distribute a cash dividend of 1.17 yuan per 10 shares [33]

| 证券代码：605366 | 证券简称：宏柏新材 公告编号：2025-061 | | --- | --- | | 债券代码：111019 | 债券简称：宏柏转债 | 江西宏柏新材料股份有限公司 关于签订募集资金协定存款协议的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、募集资金的基本情况 经中国证券监督管理委员会《关于同意江西宏柏新材料股份有限公司向不 特定对象发行可转换公司债券注册的批复》（证监许可〔2024〕108 号）批复， 公 司 向 不 特 定 对 象 发 行 可 转 换 公 司 债 券 ， 募 集 资 金 总 额 为 人 民 币 960,000,000.00元，扣除本次承销保荐费11,500,000.00元，募集资金净额为人 民币948,500,000.00元。中汇会计师事务所（特殊普通合伙）对本次发行的可 转换公司债券资金到位情况进行了验资，并于2024年4月23日出具了中汇会验 [2024]5260《验资报告》。公司已对可转换公司债券募集资金进行专户管理， 并与开户银行、保荐机构签订了《募集资金专 ...

证券代码：605366 证券简称：宏柏新材 公告编号：2025-060 债券代码：111019 债券简称：宏柏转债 江西宏柏新材料股份有限公司 关于使用部分闲置募集资金进行现金管理到期赎回 并继续进行现金管理的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 序号 | 委托理财产品名称 | | | | | 委托理财期限 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1 | 银行定期存款 | 2025 | 年 | 6 | 月 20 | 日-2025 | 年 | 12 月 | 20 | 日 | 履行的审议程序:江西宏柏新材料股份有限公司（以下简称 "公司"）于 2025 年 4 月 28 日召开第三届董事会第十九 次会议和第三届监事会第十三次会议，审议通过了《关于 拟使用部分闲置可转换公司债券募集资金进行现金管理的 议案》，同意公司使用不超过人民币 70,000.00 万元（含 本数）闲置可转换 ...

| 证券代码：605366 | 证券简称：宏柏新材 | 公告编号：2025-059 | | --- | --- | --- | | 债券代码：111019 | 债券简称：宏柏转债 | | 根据中国证监会《关于上市公司实施员工持股计划试点的指导意见》及《上 市公司自律监管指引第1号——规范运作》规定，公司2022年员工持股计划（以 下简称"本次员工持股计划"）的锁定期将于2025年6月23日届满，现将本次员工 持股计划第三批股票锁定期届满相关情况公告如下： 一、员工持股计划持股情况和锁定期 2022 年 6 月 24 日，公司收到中国证券登记结算有限责任公司出具的《过户 登记确认书》，公司回购专用证券账户中所持有的 330.00 万股公司股票已于 2022 年 6 月 23 日以非交易过户的方式过户至公司 2022 年员工持股计划证券账户，过 户价格为 7.03 元/股。截至本公告披露日，公司员工持股计划账户持有公司股份 330.00 万股，占截止本公告披露日公司总股本的比例为 0.98%。 非交易过户完成后，公司实施了 2021 年度权益分派方案和 2022 年度权益分 派方案，因此，公司 2022 年员工持 ...

Core Points - The document outlines the management system for futures and derivatives trading at Jiangxi Hongbai New Materials Co., Ltd, aiming to standardize trading behavior, prevent investment risks, and protect the interests of the company and its shareholders [1][2] - The company must adhere to principles of legality, prudence, safety, and effectiveness in its trading activities, ensuring a robust internal control system and risk management [1][2] - The company is prohibited from using raised funds for futures and derivatives trading, emphasizing the importance of focusing on its main business [2] Section Summaries General Principles - Futures trading refers to transactions involving futures contracts or standardized options, while derivatives trading includes swaps, forwards, and non-standardized options [1] - The company must analyze the feasibility and necessity of investments, establish strict decision-making procedures, and define specific requirements for authorization and information disclosure [1][2] Approval Authority - A feasibility analysis report must be prepared and submitted to the board of directors for review before engaging in futures and derivatives trading [4] - Certain trading scenarios require shareholder approval if they exceed specified thresholds related to net profit and net assets [4] Professional Management - The company will establish a leadership group responsible for organizing and overseeing futures and derivatives trading, ensuring compliance with approved plans [9] - Different departments are designated for managing trading operations, market analysis, and financial management, ensuring a structured approach to trading activities [6][12] Risk Control - Strict separation of duties is mandated to prevent conflicts of interest among trading, finance, and audit personnel [14] - The company must implement stop-loss limits and regularly assess market risks, reporting findings to the leadership group and board of directors [8] Information Disclosure - The company must disclose significant losses or gains related to futures and derivatives trading that meet specified thresholds [19] - Information regarding the purpose, types, and expected financial commitments of proposed trading activities must be disclosed to ensure transparency [20] Confidentiality - All personnel involved in trading must adhere to confidentiality protocols, preventing unauthorized disclosure of sensitive trading information [22][10] Miscellaneous - The management system will be revised as necessary to comply with relevant laws and regulations, and it will take effect upon approval by the board of directors [24][25]

证券代码：605366 证券简称：宏柏新材 公告编号：2025-058 债券代码：111019 债券简称：宏柏转债 江西宏柏新材料股份有限公司 重要内容提示： (二)股东大会召集人：董事会 召开的日期时间：2025 年 7 月 8 日 14 点 30 分 召开地点：江西省乐平市塔山工业园区宏柏新材应用中心办公室 (五)网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东会网络投票系统 网络投票起止时间：自2025 年 7 月 8 日 至2025 年 7 月 8 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东大会召开当日的交易时间段，即 9:15-9:25,9:30-11:30，13:00-15:00；通过 互联网投票平台的投票时间为股东大会召开当日的 9:15-15:00。 关于召开2025年第二次临时股东大会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 (六)融资融券、转融通、约定购回业务账户和沪股通投资者的投票程序 涉及融资融券、转融通业务、约定购回业务相关账户以及沪 ...

Group 1 - The board of directors of Jiangxi Hongbo New Materials Co., Ltd. held its 20th meeting of the third session on June 19, 2025, with all 9 directors present, confirming compliance with relevant laws and regulations [1][2]. - The board approved the proposal to revise the "Derivatives Trading Management System" [1][2]. - The board also approved the proposal to engage in commodity futures hedging and trading, with a maximum margin investment of RMB 40 million and a maximum contract value of RMB 200 million at any single point in time, valid for 12 months from the date of shareholder meeting approval [2][3]. Group 2 - The board agreed to convene the second extraordinary general meeting of shareholders in 2025 on July 8, 2025, to discuss the aforementioned proposals requiring shareholder approval [2][3]. - All proposals received unanimous support from the board, with 9 votes in favor and no votes against or abstentions [2][3].